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Abstract
Bats are rich reservoir hosts for a variety of viruses, many of which are capable of spillover to other susceptible mammals
with lethal consequences. The ability of bats to remain asymptomatic to viral infection may be due to the rapid control of
viral replication very early in the immune response through innate antiviral mechanisms. Type I and III interferons (IFNs)
represent the first line of defence against viral infection in mammals, with both families of IFNs present in pteropid bats. To
obtain further insight into the type III IFN system in bats, we describe the characterization of the type III IFN receptor (IFNlR)
in the black flying fox, P. alecto with the characterization of IFNlR1 and IL10R2 genes that make up the type III IFN receptor
complex. The bat IFNlR complex has a wide tissue distribution and at the cellular level, both epithelial and immune cells are
responsive to IFN-l treatment. Furthermore, we demonstrate that the bat IFNlR1 chain acts as a functional receptor. To our
knowledge, this report represents the first description of an IFN receptor in any species of bat. The responsiveness of bat
cells to IFN-l support a role for the type III IFN system by epithelial and immune cells in bats.
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Introduction
The hallmark of the innate immune response to viral infection is
the production of interferons (IFNs). IFNs play an essential role in
the induction of an antiviral state and contribute to the initiation of
the adaptive immune response. The type I IFNs (including IFN-a
and IFN-b) are well known for their induction and potent antiviral
activity directly in response to viral infection. More recently, a
family of IFNs named type III IFNs (also known as IL28/29 or
IFN-ls) were discovered in the human genome based on their
similarity to type I IFN and IL-10 family members [1,2]. Type I
and III IFNs have similar antiviral activity, are produced by
common pathways and result in the production of an overlapping
repertoire of interferon stimulated genes (ISGs) [3–5]. Despite
their similarities, type I and III IFNs signal through distinct IFN
receptor (IFNR) complexes and display differences in their tissue
and cellular distribution patterns consistent with each IFN family
playing a distinct role in the immune response to viral infections.
Both type I and III IFNs induce their activity by signalling
through a heterodimeric class II cytokine receptor. Type I IFNs
signal through a receptor complex composed of IFNR alpha 1
(IFNAR1) and IFNAR2 chains while type III IFNs signal through
a receptor composed of IFNlR1 (also known as IL-28Ra) and
IL10R2 (also known as IL10Rb) chains [5]. The IFNlR1 chain
serves as a unique subunit of the type III receptor complex and is
critical to the specificity of ligand binding [5]. In contrast, IL10R2
also forms part of the receptor complex of several members of the
IL-10 cytokine family, including IL-10, IL-22 and IL-26 [6–9].
The IL10R2 chain plays little role in ligand specificity but
participates in the signalling cascade leading to the induction of
ISGs.
The type III IFNR complex has only been characterized in
humans and mice and in the amphibian, Xenopus tropicalis
[1,2,10,11]. Unlike the ubiquitously expressed type I IFNR
complex, the type III IFNR has a more restricted tissue
distribution pattern. Although the IL10R2 chain is ubiquitously
expressed in all tissues and cells, the expression of the IFNlR1
varies widely between different organs and at the cellular level is
restricted to epithelial cells [5,12–14]. This expression pattern may
reflect a role for type III IFNs in antiviral activity at the major
portals of viral entry, providing a mechanism to inhibit viral
replication prior to the activation of other components of the
immune system. Although a high expression of IFNlR1 has also
been detected in a variety of human and mouse immune cells, only
mouse plasmacytoid dendritic cells have been shown to respond to
IFN-l [5,12,13,15,16].
Bats have been implicated as the natural reservoir for many of
the most deadly viruses to have emerged in recent years, including
SARS-Coronavirus (SARS-CoV), Ebola, Marburg, Hendra and
Nipah virus. Bats generally show no symptoms of disease and
appear to be capable of rapidly controlling viral replication to very
low levels yet still allowing occasional spillover to other susceptible
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of viral replication in bats are not understood, the co-evolution of
bats with viruses may have resulted in the evolution of novel
mechanisms for the control of viral replication. To elucidate the
mechanisms responsible for the asymptomatic nature of viral
infections in bats, we are using the black flying fox, Pteropus alecto as
a model species for examining antiviral immunity in bats [18–21].
Previously we demonstrated that pteropid bats have two
transcribed IFN-l genes that are differentially induced relative
to each other and to type I IFNs following dsRNA stimulation and
viral infection. Bat IFN-l2 also demonstrates significant antiviral
activity in vitro [21]. As the biological activity of cytokines is
mediated through binding to specific receptor complexes,
information on cellular responses to cytokines provides important
clues to biological function. Towards a better understanding of the
bat type III IFN system, we report the molecular cloning and
functional characterization of IFNlR1 and IL10R2 encoding the
type III IFNR complex from P. alecto. Our results demonstrate that
IFNlR1 has a wide tissue distribution with epithelial cells and
immune cells responsive to IFN-l in pteropid bats.
Materials and Methods
Cell culture
The generation of the P. alecto cell lines and culture conditions
have been described previously [18,21]. Six bat cell lines were
used, including one cloned and immortalised kidney cell line
(PaKiT01) and five primary cell lines originating from kidney,
small intestine, brain, liver and lung, respectively [18]. Bat cell
lines were cultured in DMEM/F12-Hams (Sigma), supplemented
with 10% foetal calf serum (FCS, Hyclone), 100 units/ml
penicillin, 100 mg/ml streptomycin and 50 mg/ml gentamycin
(Sigma). All cells were maintained in a humidified atmosphere of
5% CO2 in air at 37uC.
The isolation of fresh splenocytes from P. alecto bats has been
described previously [21]. Briefly, cell suspensions were prepared
by pressing spleen tissue through a cell strainer using a syringe
plunger. Mononuclear splenocytes were isolated by density
centrifugation over lymphoprep (Axis-Shield). Culture media for
mononuclear splenocytes consisted of DMEM supplemented with
10% FCS, 15 mM Hepes, 15 mM L-glutamine, 100 mg/ml
penicillin and 100 mg/ml streptomycin. All animal experiments
were approved by the Australian Animal Health Laboratory
(AAHL) animal ethics committee (protocol number 1389).
Cloning of IFN-l receptor genes
Total RNA was extracted from P. alecto fresh spleen and thymus
and polyI:C transfected PaLuT02 cells as described previously
using the RNeasy mini kit (Qiagen) with on-column DNase-I
treatment (Qiagen) [21]. Full-length coding sequences for IFNlR1
and IL10R2 were obtained using 59 and 39 rapid amplification of
cDNA ends (RACE) polymerase chain reactions (PCRs). Reac-
tions were performed on RNA extracted from polyI:C stimulated
PaLuT02 cells using the GeneRacer Kit (Invitrogen, Carlsbad,
CA, USA) with Long-amp DNA polymerase (New England
Biosystems). Primers were designed based on P. vampyrus genome
sequence information deposited in the Ensembl Genome Browser
(assembly pteVam1, 2.633 coverage, July 2008) and are listed in
Table S1. To obtain all potential isoforms of IFNlR1 and
IL10R2, RT-PCR was also performed on RNA extracted from
polyI:C stimulated PaLuT02 cells, spleen and thymus using
primers listed in Table S1. To confirm the presence of introns
within the 39-UTR of IFN-lR1, PCR was performed on genomic
DNA extracted from P. alecto liver using primers IFN-lR1-2F/6R
listed in Table S1. The resultant RACE and PCR products were
cloned and sequenced using the TOPO TA Cloning Kit
(Invitrogen) and BigDye Terminator Cycle Sequencing Kit v3.1
respectively (Applied Biosystems, Foster City, CA, USA).
Sequence analysis
Sequences were edited using SeqMan PRO (Lasergene) and
assembled manually using Clone Manager 9.0 (Sci-Ed Software).
To determine the intron-exon organization of P. alecto IFNlR1
and IL10R2 genes, the full length coding sequences were aligned
with the corresponding sequences in the P. vampyrus genome.
Intron-exon maps of the genes were drawn using Fancy Gene v1.4
(http://host13.bioinfo3.ifom-ieocampus.it/fancygene/). Putative
protein sequences for bat IFNlR1 and IL10R2 were compared
with sequences in the GenBank database using the BLASTP
algorithm [22]. Sequence alignments were performed using the
Clustal X program [23] and visualized using GeneDoc (www.
nrbsc.org/gfx/genedoc/index.html). Transmembrane regions and
Signal peptides were identified by TMHMM 2.0 and SignalP
version 3.0 respectively (www.cbs.dtu.dk/services). The GenBank
accession numbers for sequences used in the sequence alignment
are as follows (amino acid/mRNA): NP_734464/NM_170743,
Homo sapiens (human); NP_777276/NM_174851, Mus musculus
(mouse); XP_001917953/XM_001917918, Equus caballus (horse).
Quantitative reverse transcription PCR (qRT-PCR)
cDNA from ten fresh P. alecto tissues, including lymph nodes,
PBMC, brain, heart, kidney, liver, spleen, small intestine, lung and
salivary gland from three individual bats were prepared previously
[20]. RNA from IFN-l2 treated bat PaKiT02 cells and primary
cells lines derived from kidney, small intestine, brain, liver and
lung was also extracted as described for RACE PCR. qRT-PCR
primers for IFNlR1 and IL10R2 were designed using Primer
Express 3.0 (Applied Biosystems) with default parameter settings
and are listed in Table S1. Primers for ISG56, RIG-I and 18s
rRNA have been described previously [20,21]. Reactions were
carried out using EXPRESS SYBRH GreenER
TM qPCR Super-
mix Universal (Invitrogen) for cDNA and SuperScriptH III
PlatinumH SYBRH Green One-Step qRT-PCR Kit (Invitrogen)
for RNA in an Applied Biosystems 7500 Fast Real-Time qPCR
instrument. For each reaction from cDNA, 2 ml of 1:5 diluted
cDNA were used while in a reaction from RNA, 2 ml RNA per
well were used. A final concentration of 200nmol each primer was
used in these reactions.
The cycling profile for cDNA samples consisted of an initial
denaturation at 90uC for 1 minute followed by 40 cycles of 90uC
for 15 seconds, 60uC for 1 minute followed by melt curve analysis.
For that of RNA, an initial reverse transcription step at 50uC for
2 min was added. Expression level of the target genes were
calculated using either standard curves method (IFNlR1 and
IL10R2) or fold induction compared to the mock (ISG56 and
RIG-I). All data were normalised relative to the housekeeping
gene 18s rRNA.
Treatment of the bat cells with recombinant IFN-l2
IFN-l2 containing supernatant derived from a stable cell line
expressing IFN-l2 in 293T cells [21], was used to treat the bat
cells. Bat cloned kidney cells, PaKiT01 and primary bat cell lines
from kidney, small intestine, brain, liver, lung and fresh
splenocytes were treated with 1:2 diluted IFN-l2 containing
supernatant. This dilution was chosen based on the antiviral
activity of recombinant IFN-l2 described previously [21].
Supernatant from normal cultured 293T cells was used as mock
Bat Type III Interferon Receptor
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into buffer RLT (Qiagen) for extraction of total RNA.
Plasmid construction and transfection
The bat IFNlR1 full-length open reading frame (ORF) was
cloned into the pCAGGS transient expression vector with an in-
frame C-terminal 66His tag using the primers listed in Table S1.
Correct cloning was confirmed by sequencing. The plasmid was
prepared using PureYield kit (Promega) before transfection.
Approximately 1610
5 bat PaKiT01 cells were seeded into 24-
well plates. The plasmid was transfected into PaKiT01 cells using
the Neon electroporation transfection system (Invitrogen). Before
transfection, bat PaKiT01 cells were resuspended. All transfection
reactions were performed according to the manufacturer’s
instructions.
Results
Characterization of IFN-l receptor genes
IFNlR1 and IL10R2 were identified by key word searches of
the low coverage whole genome sequence of the pteropid bat, P.
vampyrus in the publicly available Ensembl database using the
terms IL28Ra and IL10Rb. The regions containing the IL10R2
and IFNl R1 genes in the current P. vampyrus whole genome
assembly shared a high degree of conserved synteny with the
corresponding regions in the human and mouse genomes.
Previously identified immune genes from P. alecto and P. vampyrus
including IFNs and TLRs have a high sequence similarity to each
other [20,21]. IFN-l 2 genes for example, share 98% nucleotide
identity between the two species. In view of the high sequence
similarity between genes previously identified in P. vampyrus and P.
alecto [20,21], IFNlR sequences from P. vampyrus were used to
design oligonucleotide primers to amplify full length cDNAs from
P. alecto. RACE PCR was performed on RNA extracted from the
bat lung cell line, PaLuT02, three hours following stimulation with
polyI:C [21]. As soluble variants of IFNlR1 and IL10R2 have
been identified in other species, RT-PCR was also performed on
P. alecto spleen and thymus RNA, however, no additional isoforms
were identified. Alignment of cDNA sequences with the P. vampyrus
genome and genes from the other species available in the
GenBank database, revealed the presence of a single form of
IFNlR1 and IL10R2 in P. alecto. These sequences have been
deposited into Genbank under accession numbers: JN000223
(IFNlR1) and JN000224 (IL10R2).
The genomic organization of each locus was determined by
aligning the complete cDNA sequences of IFNl1 and IL10R2
with the corresponding P. vampyrus genomic sequence (Fig. 1).
Similar to human IFNlR1, the bat IFNlR1 locus contains seven
exons and six introns in the region corresponding to the open
reading frame (ORF). However, bat IFNlR1 is unusual in that it
contains two additional introns in the 39-UTR region. The
presence of these introns in the 39-UTR of IFNlR1 was further
confirmed by PCR using P. alecto genomic DNA. The bat IL10R2
locus shares the same genomic structure as human IL10R2, with
seven exons and six introns. As shown in Figure 1, the two bat
IFNlR loci contain several introns that are shorter than those
present in the corresponding human loci, resulting in the bat loci
being more constrained in size. Human IFNlR1 and IL10R2
each span approximately 30kb compared with the bat loci which
are 17kb and 20kb respectively (Fig. 1).
An alignment of the full length deduced protein sequences of
bat IFNlR1 and IL10R2 with sequences from other species is
shown in Figures 2A and 2B. Deduced proteins encoded by
IFNlR1 and IL10R2 contained many of the conserved features
present in human genes. Bat IFNlR1 contained an ORF of
1548 bp, encoding a protein of 515 amino acids (aa) with a 25 aa
putative signal peptide (Fig. 2A). A 23 aa transmembrane region
encoded by exon six separates the protein into a 203 aa
extracellular domain and 265 aa intracellular domain. The
deduced protein sequence was highly conserved with that of other
mammals including the presence of six conserved cysteine residues
in the extracellular region and three tyrosines in the intracellular
region, two of which (Y344 and Y512) are essential for STAT2
and STAT5 activation [24]. The P. alecto IFNlR1 sequence
shared 66–79% nucleotide identity and 50-65% amino acid
identity with IFNlR1 genes from other mammals (Table 1).
Bat IL10R2 contained an ORF of 984 bp, encoding a 327 aa
protein. The 24 aa transmembrane region (221 to 244 aa) encoded
by exon 6 separated the protein into a 201 aa extracellular region
and 83 aa intracellular region. These features are highly conserved
with human IL10R2. Bat IL10R2 has four conserved cysteine
residues in the extracellular region and two conserved tyrosine
residues in the intracellular region (Fig. 2B). The P. alecto IL10R2
sequence shared 75-85% nucleotide identity and 63–78% amino
acid identity with IL10R2 genes from other mammals (Table 2).
IFNlR1 and IL10R2 are transcribed in a variety of organs
in P. alecto
To examine the tissue distribution of bat IFNlR1 and IL10R2,
we determined their transcription in a range of P. alecto primary
organs. As show in Figure 3A, IFNlR1 is transcribed in all organs
tested with small intestine and spleen showing the highest
transcription and brain the lowest. IL10R2 also appeared to be
Figure 1. Gene organization of P. alecto IFNlR1 and IL10R2 compared with that of corresponding human genes. The intron-exon
structures were predicted by nucleotide alignment of IFNlR1 or IL10R1 mRNA with the corresponding sequences in either the P. vampyrus or human
genome sequences. Putative UTRs and exons are drawn as rectangles; introns are shown as dotted lines.
doi:10.1371/journal.pone.0025385.g001
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between organs was detected in the expression of IL10R2
compared with IFNlR1 (Fig. 3B). The three immune related
cells and organs, PBMC, spleen and lymph nodes had the highest
expression of IL10R2. Brain, heart and kidney showed much
lower transcription levels of IL10R2 compared to the other organs
tested (Fig. 3B).
IFN-l targets epithelial cells in non- hematopoietic cell
lines
In view of the ubiquitous tissue distribution of bat IFNlR1, we
next sought to determine the sensitivity of cell lines derived from
different P. alecto tissues to IFN-l treatment. In humans, the
IFNlR1 chain is unique to the IFNlR complex and has
substantially higher ligand affinity than the IL10R2 chain
[3,6,7,14]. We therefore focused on IFNlR1 to obtain information
specific to the IFN-l response. Bat primary cells, including five
non-hematopoietic cell lines derived from kidney, small intestine,
brain, liver and lung were examined for their response to
recombinant bat IFN-l2 [21]. As shown in Figure 4, there is a
correlation between the expression of IFNlR1 (Fig. 4A) and the
induction of the two ISGs tested, RIG-I (Fig. 4B) and ISG56
(Fig. 4C) following IFN-l stimulation. Liver, lung and small
intestine which have relatively higher IFNlR1 expression show
correspondingly high ISGs induction. In contrast, kidney and
brain responded poorly to IFN-l, due to their low IFNlR1
expression.
Figure 2. Alignment of the deduced amino acid sequence of P. alecto IFNlR1 (A) and IL10R2 (B) genes with human, mouse and horse
IFNlR sequences. Signal peptides are underlined and transmembrane regions are shaded. The conserved cysteine and tyrosine residues are in
bold. Two of the tyrosine residues in IFNlR1, which are involved in meditation of STAT2 tyrosine phosphorylation in human IFNlR1 are conserved in
bat IFN-lR1 and are further boxed. Dashes indicated similarity and dots indicate gaps.
doi:10.1371/journal.pone.0025385.g002










Bat-IFNlR1 69 54 65
Human-IFNlR1 79 57 63
Mouse-IFNlR1 66 69 50
Horse-IFNlR1 75 74 64
Bold numbers indicate amino acid identity; non-bold numbers represent
nucleotide identity.
doi:10.1371/journal.pone.0025385.t001










Bat-IL10R2 82 69 78
Human-IL10R2 85 69 78
Mouse-IL10R2 75 76 63
Horse-IL10R2 84 83 72
Bold numbers indicate amino acid identity; non-bold numbers represent
nucleotide identity.
doi:10.1371/journal.pone.0025385.t002
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adherent tissue cell types and are not a direct reflection of the
original tissue they were derived from. In humans, the IFNlR1
expression among non-hematopoietic cells is restricted to epithelial
cells [5]. To determine whether a similar pattern exists in bats we
used a cross-specific epithelial cell marker (anti-cytokeratin) to
determine the proportion of epithelial cells in each cell line
population. The Western blot shown in Figure 4D illustrates the
relative proportion of epithelial cells in each cell line population
and demonstrates a correlation between the proportion of
epithelial cells within the cell line populations, their IFNlR1
expression and ISGs production (Fig. 4).
Immune cells express IFNlR1 and respond to IFN-l
treatment
To further investigate the cellular responsiveness to IFN-l,w e
examined the response of freshly isolated bat splenocytes, a rich
source of immune cells. As shown in Figure 5, the bat immune
cells have much higher IFNlR1 expression compared with the
tissue cell types present in the primary cell lines (Fig. 4A).
Following treatment with recombinant bat IFN-l2, the transcrip-
tion of RIGI and ISG56 was upregulated over four and three fold
respectively, representing a moderate ISG induction. Overall,
these results demonstrate that immune cells express high levels of
IFNlR1 and are responsive to IFN-l treatment.
IFNlR1 is a functional receptor of IFN-l
To assess whether IFNlR1 is a functional receptor for IFN-l,w e
constructed a transient expression vector containing the full length
ORF of IFNlR1 with a C-terminal His-tag. Successful construction
was confirmed by sequencing. To demonstrate the functional
activity of bat IFNlR1 in bat cells, the cloned and immortalized bat
kidney cell line, PaKiT01 was transfected with IFNlR1. This cell
line was chosen due to the low level of native IFNlR1 expression
detected in these cells compared to other bat cell lines tested
(unpublished data). Recombinant bat IFN-l2 was used to stimulate
the IFNlR1 transfected bat PaKiT01 cells for six hours and
IFNlR1 and ISG induction was measured by qRT-PCR following
DNaseI treatment to remove carry over plasmid DNA. As shown in
Fig. 6, compared to mock transfected cells, a 1000 fold induction of
Figure 3. qRT-PCR detection of IFNlR1 (A) and IL10R2 (B) mRNA expression in P. alecto. PBMC: peripheral blood mononuclear cells. The
expression level was normalized to housekeeping gene 18s rRNA. n=3 individual apparently healthy wild-caught bats. The error bars represent
standard deviation in (A) and (B).
doi:10.1371/journal.pone.0025385.g003
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strating successful transfection. Treatment of IFNlR1 transfected
cells with recombinant bat IFN-l resulted in a 600 fold induction of
ISG56 and 36 fold induction of RIG-I. No ISG induction was
observed in mock transfected or mock treated cells (Fig. 6).
Discussion
Bats are rich reservoirs of emerging and re-emerging viruses
[17], yet their immune response to viral infection is poorly
understood. Type III IFNs are a recently discovered family of
IFNs that share a number of functional characteristics with type I
IFNs but signal through a different IFNR complex. Bat type III
IFNs display antiviral activity similar to mammalian type I IFNs
and have been demonstrated to be transcribed in virus infected bat
cells despite the suppression of type I IFNs [21]. The genes
encoding the bat type III IFNR complex, IFNlR1 and IL10R2
Figure 4. The responsiveness of P. alecto non-haematopoietic
cell lines to IFN-l2 treatment correlates with IFNlR1 expres-
sion and proportions of epithelial cells. (A) Relative expression
level of IFNlR1 by qRT-PCR (mean of two experiments). The expression
level was normalized to the housekeeping gene 18s rRNA. (B/C)
Responsiveness of P. alecto kidney, small intestine, brain, liver and lung
primary cells. The histogram shows the (B) RIG-I or (C) ISG56 fold
induction in response to IFN-l2 treatment (mean of two experiments).
The error bars represent standard errors in (A), (B) and (C).(D) The
relative proportion of epithelial cells in the primary cell cultures as
demonstrated by Western blotting using an anti-cytokeratin antibody.
The housekeeping gene, GAPDH was used as a loading control.
doi:10.1371/journal.pone.0025385.g004
Figure 5. Responsiveness of P. alecto splenocytes to IFN-l2
treatment and the relative expression level of IFNlR1. Cells
were treated for 6 hours before they were collected for RNA extraction
and qRT-PCR analysis. The left axis shows the relative expression level of
IFNlR1 (mean of three experiments). The right axis shows the ISG56 and
RIG-I fold induction in response to IFN-l2 treatment (mean of three
experiments). The expression level was normalized to the housekeeping
gene 18s rRNA. The error bars represent standard errors.
doi:10.1371/journal.pone.0025385.g005
Figure 6. IFNlR1 is a functional receptor of IFN-l2. Bat cloned
and immortalized cell line PaKiT01 cells were transfected with IFNlR1
expression plasmid or empty vector for 24 hours, followed by IFN-l2
treatment (or mock treatment) for another 6 hours. After which, cells
were collected and total RNA was extracted for qRT-PCR analysis.
IFNlR1, ISG56 and RIG-I mRNA expression were tested and indicated by
relative expression (mean of two experiments). The error bars represent
standard errors.
doi:10.1371/journal.pone.0025385.g006
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genome sequence of the Malaysian flying fox, P. vampyrus and
further characterized in the closely related pteropid bat, P. alecto.
Bat IFNlR1 and IL10R2 share a similar genomic organization to
their human counterparts and are highly conserved with other
mammalian IFNlR genes.
In humans there are two splice variants of the IFNlR1 chain,
encoding a soluble receptor and a truncated transmembrane
receptor [5]. No alternative splice variants of IFNlR1 were
identified in P. alecto, despite extensive screening of spleen and
thymus RNA by RT-PCR. The two splice variants of human
IFNlR1 have been speculated to negatively regulate IL-28/IL-29
signalling as a result of IFN-l binding to the soluble IFNlR1
receptor prior to cell contact, and due to the truncated IFNlR1
acting as a dominant negative receptor chain. Although we cannot
completely rule out the possibility of the presence of additional
IFNlR1 splice variants in P. alecto, the absence of such variants
with the ability to downregulate the IFN-l response may lead to a
more pronounced IFN response in bat cells.
In contrast to the ubiquitously expressed type I IFNR, there is
considerable variation in type III IFNR expression between organs
and even between the few species in which it has been
characterised. In humans and Xenopus, the IFNlR1 chain is
expressed by a range of tissues with a high level of variation, being
highest in lung, heart and immune organs and lowest in the brain
[1,2,10,12]. In mice, IFNlR1 is expressed predominantly in
stomach, small intestine and skin and is expressed at very low
levels in the central nervous system and spleen [13,16,25]. Our
results demonstrate a ubiquitous IFNlR1 expression pattern in all
tissues tested in P. alecto, however, similar to humans and Xenopus,
considerable variation exits between tissues with small intestine
and spleen having relatively higher expression of IFNlR1
compared to other organs. The transcription of P. alecto IL10R2
was comparable to humans [25], with a ubiquitous expression
among all tissues tested. Interestingly, the three hematopoietic
organs tested, PBMC, spleen and lymph nodes displayed the
highest IL10R2 expression likely reflecting its role as a receptor for
a number of cytokines. This expression pattern correlates with the
pattern of TLR7, 8 and 9 expression in P. alecto [20].
At the cellular level, bat IFNlR1 is capable of responding to
stimulation with IFN-l, providing evidence that it is a functional
receptor. In humans and mice, IFNlR1 appears to be restricted to
epithelial cells [12,13]. To determine whether a similar situation
exists in bats, we used a number of primary cell lines derived from
different P. alecto organs and examined their IFNlR1 expression
and response to IFN-l stimulation. Our results demonstrate a
clear relationship between IFNlR1 expression and response to
IFN-l stimulation. In addition, this pattern correlated with the
proportion of epithelial cells in the selected bat cell lines. The
restricted expression pattern of IFNlR1 in non-haematopoietic
cells is similar to other species and is consistent with a role for IFN-
l in contributing to the elimination of viruses at the major portals
of entry into the body before infection is established.
To investigate the role of IFN-l in hematopoietic cells, we
examined IFNlR1 expression and response to IFN-l in freshly
isolated bat splenocytes which are a rich source of immune cells.
Bat spleen cells displayed a high IFNlR1 expression and
responded to IFN-l treatment with the induction of RIG-I and
ISG56. However, a higher IFNlR1 expression by bat splenocytes
compared with the non-hematopoietic cell lines did not corre-
spond to a higher induction of ISGs. In mice, plasmacytoid
dendritic cells are the only immune cells that express the IFNlR1
and these cells are also responsive to IFN-l stimulation [16].
Human immune cells including B, T and NK cells express high
levels of IFNlR1 mRNA, and PBMCs have membrane bound
IFNlR1, however, they show little response to stimulation with
IFN-l [12]. Our results are consistent with the presence of a
population of bat splenocytes that are sensitive to IFN-l.
However, in the absence of specific cell markers to characterize
bat immune cells we are unable to determine which populations of
cells express IFNlR1 and respond to IFN-l. Characterization of
the immune cell types capable of responding to IFN-l during viral
infection will provide further insights into the role of IFN-l in
antiviral immunity in bats.
To our knowledge, our results provide the first molecular
characterization of the IFNlR system in any species of bat,
demonstrating that bat IFNlR1 serves as a functional IFN-l
receptor. We previously described the upregulation of type III IFN
in virus infected bat cells, despite the suppression of the type I IFN
response [21]. The distribution and functional activity of IFNlR1
in both epithelial and immune cells provides additional support for
an important role for IFN-l in the antiviral immune response of
bats.
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